Compugen Ltd. (TLV:CGEN)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 622.71M +1.7% |
| Revenue (ttm) | 231.97M +161.1% |
| Net Income | 112.67M |
| EPS | 1.21 |
| Shares Out | n/a |
| PE Ratio | 5.53 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,156 |
| Average Volume | 47,958 |
| Open | 653.30 |
| Previous Close | 653.30 |
| Day's Range | 653.30 - 710.10 |
| 52-Week Range | 435.00 - 760.00 |
| Beta | 2.96 |
| RSI | 62.56 |
| Earnings Date | Mar 2, 2026 |
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/T... [Read more]
News
Compugen Reports Fourth Quarter and Full Year 2025 Results
Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029 Enhanced leaders...
Compugen to Participate in Upcoming Investor Conferences
HOLON, Israel, Feb. 19, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/...
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
HOLON, Israel, Feb. 17, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI...
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
HOLON, Israel, Feb. 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI...
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
Non-dilutive strategic transaction expected to extend cash runway into 2029, to advance Compugen's innovative immuno-oncology pipeline and to reach potential key catalysts from internal and partnered ...
Compugen Reports Third Quarter 2025 Results
COM701 Phase 1 data presented at ESMO 2025 characterized patients who derived clinical benefit and informed the design of the ongoing MAIA-ovarian platform trial Enrolling patients in the U.S., Israel...
Compugen to Participate in Stifel 2025 Healthcare Conference
HOLON, Israel , Nov. 4, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery po...
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
HOLON, Israel , Oct. 27, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery p...
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
Pooled analysis supports the rationale for the ongoing MAIA-ovarian trial evaluating COM701 as maintenance therapy in the earlier setting of platinum sensitive ovarian cancer HOLON, Israel , Oct. 13, ...
Compugen to Present at SITC 2025
HOLON, Israel , Oct. 6, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery, powered...
Compugen to Present Research at the Single Cell Genomics 2025 Conference
HOLON, ISRAEL , Sept. 8, 2025 /PRNewswire/ -- Compugen Ltd.
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
HOLON, Israel , Aug. 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powere...
Compugen Reports Second Quarter 2025 Results
First patient dosed in MAIA-ovarian platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in July 2025 Pooled analysis from three previously reported Phase 1 ...
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
HOLON, Israel , July 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery po...
Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
HOLON, Israel , July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery p...
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer
Randomized sub-trial 1 of a global adaptive platform trial of COM701 maintenance therapy in patients with relapsed platinum sensitive ovarian cancer Trial supported by strong biological rationale and ...
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
HOLON, Israel , June 12, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced t...
Compugen Reports First Quarter 2025 Results
Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025 Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM5...
Compugen Announces Leadership Transitions Effective September 2025
Anat Cohen-Dayag, Ph.D., appointed as Executive Chair of the Board of Directors Eran Ophir, Ph.D.
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025
HOLON, Israel , May 5, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th...
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
HOLON, Israel , March 26, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
Compugen Reports Fourth Quarter and Full Year 2024 Results
Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody On track to initiate a randomized adaptive platform trial of COM701 maintenanc...
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
HOLON, ISRAEL , March 3, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand tumor biology an...
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
HOLON, Israel , Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, ...